United States Oil ETF vs State Street SPDR S&P Biotech ETF — how do they compare? United States Oil ETF trades at $126.8, while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, United States Oil ETF nearer its low. Which is the better fit depends on your goals.
| USO | XBI | |
|---|---|---|
52-Week High | $152.96 | $164.28 |
52-Week Low | $66.17 | $86.92 |
Sector | — | Broad Market / Factor |
Signals from Pluang's Aura AI — not financial advice
USO trades at $127.30, up 1.1% today, with a bullish technical outlook supported by moving averages. Recent news highlights oil market volatility due to Middle East supply disruptions and OPEC demand forecast cuts. Key support lies at $126, with resistance at $129.
The stock faces upside from supply constraints but risks include demand weakness and geopolitical uncertainty. Investors should weigh bullish technicals against fundamental headwinds in oil markets for balanced positioning.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Trailing returns across standard periods
This ETF invests primarily in futures contracts for light, sweet crude oil, other types of crude oil, diesel-heating oil, gasoline, natural gas, and other petroleum-based fuels.
Read more on USO →XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →